Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
May 13 2022 - 8:00AM
Ceapro Inc. (TSX-V: CZO;
OTCQX: CRPOF) (“Ceapro” or the
“Company”), a growth-stage biotechnology company focused
on the development and commercialization of active ingredients for
healthcare and cosmetic industries, announced today that Bernhard
Seifried, Ph.D., Ceapro’s Senior Director, Research &
Technology, will give a keynote lecture titled, Aerogels &
Composites: From Concept to Applications, at the 13th International
Symposium on Supercritical Fluids (ISSF 2022) being held May 15-18,
2022 in Montréal, Québec, Canada. Dr. Seifried’s keynote lecture
will be on Monday, May 16, 2022 at 1:30 PM ET.
As part of the keynote lecture, Dr. Seifried
will discuss Ceapro’s patented Pressurized Gas eXpanded liquid
(PGX) Technology, a unique and disruptive technology with several
key advantages over conventional drying and purification
technologies that can be used to process biopolymers into
high-value, fine-structured, open-porous polymer structures and
novel biocomposites. To date, PGX has generated aerogels with many
biopolymers including alginates, pectin, oat beta glucan, gum
arabic, corn starch, nanocrystalline cellulose, and composites
consisting of yeast beta glucan and alginate.
The unique method of the PGX Technology, unlike
conventional aerogel formation procedures, does not require many
time-consuming and solvent handling steps, such as gelation,
cross-linking, and solvent exchange procedures. Furthermore, PGX
Technology allows rapid development of new aerogel composites and
exfoliated nano-composites with tunable properties (such as
dissolution and release profiles) to generate tailor-made and novel
bioactive delivery systems for nutraceuticals, drug delivery and
wound healing.
The PGX Technology is ideally suited for
processing challenging high-molecular-weight, water-soluble
biopolymers. It can make ultra-light, highly porous polymer
structures on a semi-continuous basis, which is not possible using
today's conventional technologies. PGX Technology was invented by
Dr. Feral Temelli from the Department of Agricultural, Food &
Nutritional Science of the University of Alberta (U of A) along
with Dr. Seifried. The license from U of A provides Ceapro with
exclusive worldwide rights in all industrial applications.
For more information about ISSF2022, please visit the conference
website.
About Ceapro Inc.Ceapro Inc. is
a Canadian biotechnology company involved in the development of
proprietary extraction technology and the application of this
technology to the production of extracts and “active ingredients”
from oats and other renewable resources. Ceapro adds further value
to its extracts by supporting their use in cosmeceutical,
nutraceutical, and therapeutics products for humans and animals.
The Company has a broad range of expertise in natural product
chemistry, microbiology, biochemistry, immunology and process
engineering. These skills merge in the fields of active
ingredients, biopharmaceuticals and drug-delivery solutions. For
more information on Ceapro, please visit the Company’s website at
www.ceapro.com.
For more information contact:
Jenene ThomasJTC Team, LLCInvestor Relations and Corporate
Communications AdvisorT (US): +1 (833) 475-8247E: czo@jtcir.com
Ceapro (TSXV:CZO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ceapro (TSXV:CZO)
Historical Stock Chart
From Apr 2023 to Apr 2024